Arcutis Biotherapeutics, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-95.9% vs price
Base Case (Median)
-89.7% vs price
Bull Case (75th pct.)
-81.8% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $1.04 | -95.9% | High (40%) |
| PE Comparable | $4.67 | -81.8% | Medium (25%) |
| Graham Number | $2.65 | -89.6% | Medium (40%) |
| EV/EBITDA | $0.19 | -99.2% | Medium (20%) |
| EV/FCF | $6.15 | -76.0% | Medium (20%) |
Based on 5 out of 8 methods, ARQT appears overvalued at the current price of $25.61. The base case fair value of $2.65 implies 89.7% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.